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Metallothionein (MT) is an intracellular metal-binding, cysteine-rich protein, and is a potent antioxidant that protects cells and
tissues from oxidative stress. Although the major isoforms MT-1 and -2 (MT-1/-2) are highly inducible in many tissues, the
distribution and role of MT-1/-2 in diabetic nephropathy are poorly understood. In this study, diabetes was induced in adult
male rats by streptozotocin, and renal tissues were stained with antibodies for MT-1/-2. MT-1/-2 expression was also evaluated in
mProx24 cells, a mouse renal proximal tubular epithelial cell line, stimulated with high glucose medium and pretreated with the
antioxidant vitamin E. MT-1/-2 expression was gradually and dramatically increased, mainly in the proximal tubular epithelial
cells and to a lesser extent in the podocytes in diabetic rats, but was hardly observed in control rats. MT-1/-2 expression was also
increasedbyhighglucosestimulationinmProx24cells.BecausetheinductionofMTwassuppressedbypretreatmentwithvitamin
E, the expression of MT-1/-2 is induced, at least in part, by high glucose-induced oxidative stress. These observations suggest that
MT-1/-2 is induced in renal proximal tubular epithelial cells as an antioxidant to protect the kidney from oxidative stress, and may
oﬀer a novel therapeutic target against diabetic nephropathy.
1.Introduction
Diabetic nephropathy is a leading cause of end-stage renal
disease, and many mechanisms have been proposed to ex-
plain the pathogenesis of renal injury in diabetes [1]. Recent
studies have shown that hyperglycemia may induce oxidative
stress by increasing reactive oxygen species (ROS) generation
in the diabetic kidney [2–4] and that overexpression of
the antioxidant superoxide dismutase 1 attenuated diabetic
nephropathy in streptozotocin (STZ)-induced and db/db
diabetic mice [5, 6]. Therefore, ROS could be an important
mediator of diabetic nephropathy, and protection from ROS
might oﬀer a valuable therapeutic strategy to treat diabetic
nephropathy.
Metallothionein (MT) is an intracellular metal-binding
protein with a low-molecular mass (6-7kDa) and a high
cysteine content (20 of 61-62 amino acids). Its major iso-
forms, MT-1 and -2 (MT-1/-2), are widely distributed2 Experimental Diabetes Research
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Figure 1: MT-1/-2 expression in the kidney. Diabetes was induced by injection of streptozotocin, and kidneys were obtained at 1 (a and d),
2 (b and e), or 8 (c and f) weeks after inducing diabetes. Immunoﬂuorescent staining was performed as described in Materials and Methods.
MTwasstronglyexpressedintherenalcortexofdiabeticrats(d,e,f)andhardlyexpressedincontrolrats(a,b,c).TheexpressionofMT-1/-2
was greater at week 8 than at weeks 1 and 2 after diabetes induction. Scale bar: 100μm.
throughout the body [7, 8]. Since MT-1/-2 expression is
signiﬁcantlyupregulatedbyoverloadofessentialtracemetals
(e.g., Zn and Cu), it plays an important role in heavy
metal detoxiﬁcation and essential metal homeostasis [9, 10].
In addition, MTs have been shown to act as nonspeciﬁc
free radical scavengers [11, 12], suggesting that they exert
antioxidant activities in various diseases, including diabetic
nephropathy.
We and other investigators have demonstrated that MTs
have neuroprotective eﬀects in mouse models of Parkinson’s
disease [13–15]. In contrast, the role of MTs in the patho-
genesisofdiabeticnephropathyispoorlyunderstood.Several
studies reported that renal expression of MT is increased in
STZ-induced diabetic rats [16], diabetic BB rats [17], and
ob/ob diabetic mice [18]. However, the distribution of MTs
in the diabetic kidney and the mechanisms by which MTs are
induced in diabetes are poorly understood. Therefore, in the
present study, weinvestigated the expression andlocalization
of MT-1/-2 during the development of diabetic nephropathy
and explored the mechanism by which MT-1/-2 expression
was induced by high glucose in the kidney.
2.MaterialsandMethods
2.1. Experimental Protocol. Male Sprague Dawley rats were
purchased from Charles River (Yokohama, Japan). Five-
week-old rats were divided into two groups: (1) nondiabetic
control rats (control; n = 6) and (2) STZ-induced diabetic
rats (DM; n = 6). Diabetes was induced by peritoneal
injection of 200mg/kg STZ (Sigma-Aldrich Corp., MO) in
citrate buﬀer (pH 4.5). Blood glucose was measured by the
glucose oxidase method at 3 days after STZ injection and
only rats with blood glucose concentrations >16mmol/L
were used in the study. All rats had free access to standard
diet and tap water. All procedures were performed according
to the Guidelines for Animal Experiments at Okayama
University Medical School, Japanese Government Animal
Protection and Management Law (No. 105) and the Japanese
Government Notiﬁcation on Feeding and Safekeeping of
Animals (No. 6). Rats were sacriﬁced at 1, 2, or 8 weeks after
inducing diabetes. We measured body weight, hemoglobin
A1c (HbA1c), and 24-h urinary albumin excretion (UAE)
at 1, 2, and 8 weeks. The kidneys were removed, weighed,
and ﬁxed in 10% formalin for periodic acid—methenamine
silver (PAM) staining, and parts of the remaining tissues
were embedded in optimal cutting temperature compound
(SakuraFinetechnical,Tokyo,Japan)andfrozenimmediately
in acetone cooled on dry ice.
2.2. Immunoﬂuorescent Staining of MT-1/-2 in Rat Kidney.
Immunoﬂuorescent staining was performed as previously
described [19]. Renal expression of MT-1/-2 was detected
usingmouseanti-MT-1/-2antibody(Dako,Carpinteria,CA)
followed by Alexa Fluor 594 goat anti-mouse IgG (Invit-
rogen, Carlsbad, CA). To determine whether MT-1/-2 was
localized in podocytes or proximal tubular epithelial cells,
thesectionswerecounterstainedwithguineapigantinephrin
antibody (Fitzgerald, Concord, MA) or rabbit antiaqua-
porin 1 antibody (Millipore, Billerica, MA), followed by
Alexa Fluor 488 goat anti-guinea pig IgG or anti-rabbit
IgG (Invitrogen), respectively. Fluorescence images were
obtained using a ﬂuorescence microscope (BX51; Olympus,
Tokyo, Japan).
2.3. Cell Culture and Treatment. mProx24 cells, a murine
renal proximal tubular epithelial cell line derived fromExperimental Diabetes Research 3
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Figure 2: MT-1/-2 expression in podocytes and proximal tubular cells of the kidney. Immunoﬂuorescent staining was performed as
described in Materials and Methods. Eight weeks after inducing diabetes, MT-1/-2 was predominantly expressed in the proximal tubular
epithelial cells of the kidney (b) and weakly expressed in podocytes (d) in the kidney of diabetic rats. In control rats, MT-1/-2 was weakly
expressed in proximal tubular epithelial cells (a), but hardly in the podocytes (c). AQP1: aquaporin 1, MT: MT-1/-2. Scale bar: upper panels,
200μm; lower panels, 50μm.
C57BL/6J adult mouse kidney [20], were cultured in Dul-
becco’s modiﬁed Eagle’s medium (Sigma-Aldrich Corp.)
supplemented with 1000mg/L D-glucose, 10% fetal bovine
serum, 100U/mL penicillin, and 100mg/mL streptomycin
at 37◦Ci n5 %C O 2. To evaluate the eﬀect of high glucose
on MT expression, the cells were serum-starved by culture
in 0.5% FBS for 24h, then stimulated with 4500mg/L D-
glucose(highglucose)orD-mannitol(Sigma-AldrichCorp.)
for 24h. For antioxidant treatment, the cells were pretreated
with vitamin E (Sigma-Aldrich Corp.) at concentration
ranges from 20 to 200nM for 24h, then stimulated with
high glucose for 24h. Individual experiments were repeated
at least three times with diﬀerent lots or preparations of
cells.
2.4. Quantitative Analyses of MT-1 Gene and MT-1/-2 Protein
Expression in mProx Cells. RNA was isolated from mProx
cells using an RNeasy Mini kit (Qiagen, Valencia, CA).
Single-strand cDNA was synthesized from the extracted
RNA using a RT-PCR kit (Perkin Elmer, Foster City, CA).
To evaluate the mRNA expression of MT-1 in mProx24
cells, quantitative RT-PCR (qRT-PCR) was performed using
StepOnePlus (Applied Biosystems, Tokyo, Japan) and Fast-
Start SYBR Premix Ex Taq II (Takara Bio Inc., Otsu,
Japan). The primers for the MT-1 gene (upstream 5 -
TCTAAGCGTCACCACGACTTCA-3  and downstream 5 -
GTGCACTTGCAGTTCTTGCAG-3 )w e r ep u r c h a s e df r o m
Takara Bio Inc. Each sample was analyzed in triplicate and
normalized for GAPDH mRNA expression. Immunoﬂuores-
cent staining of MT-1/-2 protein was performed as described
above. The immunoﬂuorescence intensity in cultured mProx
cells was calculated using the formula, x (density) × positive
area (μm2), using Lumina Vision software (Mitani Corpora-
tion).
2.5. Statistical Analysis. All values are means ± SEM. Statis-
tically signiﬁcant diﬀerences between groups were examined
using one-way ANOVA followed by Scheﬀ´ e’s test. Values of
P<0.05 were considered statistically signiﬁcant.
3. Results
3.1. MT-1/-2 Expression Was Increased in Diabetic Kid-
ney. MT-1/-2 expression was observed in the renal cor-
tex from 1 week after the induction of diabetes. Its
expression increased gradually and was strongly upreg-
ulated at week 8 (Figure 1,(d),(e),(f)). In contrast, MT-
1/-2 was hardly detected in the kidney of control rats
(Figure 1, (a),(b),(c)). Renal sections counterstained with
antiaquaporin 1 and antinephrin antibodies revealed that
MT-1/-2 expression was predominantly localized in the
proximal tubular epithelial cells (Figure 2(b)), and to a
lesser extent in the podocytes of the diabetic kidneys
(Figure 2(d)). In control rats, MT-1/-2 was weakly expressed
in the proximal tubular epithelial cells (Figure 2(a)), but
not in the podocytes (Figure 2(c)). Body weight, kid-
ney weight, UAE, and HbA1c are shown in Table 1.
Diabetic rats had a signiﬁcantly lower body weight and
higher kidney weight per body weight at 8 weeks, but not at
1 and 2 weeks after the induction of diabetes. Similarly, The
UAE and HbA1c level in the diabetic rats was signiﬁcantly
higher than in the control rats at 8 weeks, but not at 1
and 2 weeks. Glomerular hypertrophy and mesangial matrix
expansion, but not interstitial changes and tubular atrophyExperimental Diabetes Research 5
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Figure 3: High glucose increases MT-1 mRNA and MT-1/-2 protein expression. mProx24 cells were serum-starved for 24h before
stimulation with high glucose or mannitol. (a) Cells were harvested after 24h, and MT-1 mRNA expression was analyzed by qRT-PCR
in three independent experiments and normalized for GAPDH. (b–e) MT-1/-2 protein expression was determined by immunoﬂuorescent
staining with anti-MT-1/-2 antibody 24h after stimulation followed by densitometric analysis. Results are means ± SEM of three
independent experiments. ∗P<0.05 versus high glucose; NG: normal glucose; Man: mannitol; HG: high glucose. Scale bar: 100 μm.
were observed in the diabetic rats as compared with control
rats at 8 weeks (data not shown).
3.2. High Glucose Increased MT-1/-2 Expression in mProx24
Cells. qRT-PCR analyses revealed that exposure to the
high glucose medium signiﬁcantly increased MT-1 mRNA
expression in mProx24 cells compared with normal glucose
medium (Figure 3(a)). Similarly, high glucose, but not
mannitol,signiﬁcantlyincreasedMT-1/-2proteinexpression
in mProx24 cells (Figures 3(b)–3(e)). These data indicate
thathighglucoseincreasesthemRNAandproteinexpression
of MT-1/-2 in mProx24 cells.
3.3. MT-1/-2 Expression Was Suppressed by Vitamin E. It
is well known that high glucose increases the generation
of ROS in various cells. To investigate the mechanism
by which MT is induced by ROS in the high glucose
condition,weexaminedtheeﬀectsofanantioxidant,vitamin
E, on MT-1/-2 expression in mProx24 cells. As shown in
Figure 4, high-glucose-stimulated MT-1/-2 expression was
signiﬁcantly attenuated by vitamin E in a dose-dependent
manner (Figure 4). Accordingly, these ﬁndings suggest that
ROS generated by high glucose induces MT-1/-2 expression
in the proximal tubular epithelial cells of the kidney.
4. Discussion
There is increasing evidence from experimental and clin-
ical studies to suggest that oxidative stress plays a criti-
cal role in the pathogenesis and progression of diabetic6 Experimental Diabetes Research
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Figure 4: Vitamin E suppresses high glucose-induced MT-1/-2 expression. mProx24 cells were serum-starved and pretreated with vehicle
or vitamin E for 24h before stimulation with high glucose or mannitol. MT-1/-2 expression was determined by immunoﬂuorescent
staining. MT-1/-2 expression was not increased by mannitol (b) compared with normal glucose (a), but was increased by high glucose
(c). High glucose-induced MT-1/-2 expression was attenuated by vitamin E pretreatment in a dose-dependent manner (d: 20nM; E:
100nM; F: 200nM). The cells depicted are representative of three independent experiments. (g) Densitometric quantiﬁcation of MT-1/-
2 immunoﬂuorescence. Results are means ± SEM of three independent experiments. ∗P<0.05 versus high glucose; NG: normal glucose;
Man: mannitol; HG: high glucose; Vit E: vitamin E. Scale bar: 100μm.
complications [21]. Since MT is a potent, endogenous
and inducible antioxidant in various tissues [11, 12], we
hypothesized that MT may be induced and act as an
antioxidantinSTZ-induceddiabetickidneys.Here,wefound
that high glucose induces the expression of MT-1/-2 mainly
in proximal tubular epithelial cells and, to a lesser extent,
in podocytes in rat kidneys. MT-1/-2 was dramatically
expressed in renal proximal tubular epithelial cells within 1
week after inducing diabetes and gradually increased to week
8. MT-1/-2 expression seems to correlate with glucose level,
but not with UAE, HbA1c, interstitial abnormalities. To our
knowledge, this is the ﬁrst report describing the localization
and expression of MT-1/-2 in the diabetic kidney.
To elucidate the mechanism by which diabetes induces
MT-1/-2 expression in proximal tubular epithelial cells,
we investigated the eﬀects of high glucose stimulation on
mProx24,amurinerenalproximaltubularepithelialcellline.
We detected increased MT-1 mRNA and MT-1/-2 protein
expression in the high glucose condition and found that
high glucose-induced MT-1/-2 expression was suppressed by
pretreatment with the antioxidant vitamin E. Vitamin E is
well known to have high biological activity to protect cells
from the propagation of free radical reactions [22, 23], thus
we chose vitamin E in this study. These data suggest that
ROS and oxidative stress, which are induced by high glucose,
may be involved in the induction of MT-1/-2. AlthoughExperimental Diabetes Research 7
Table 1: Metabolic data at 1, 2, and 8 weeks after inducing diabetes.
1w e e k 2w e e k 8w e e k
Body weight (g)
Control 204 ± 6.3 241 ± 10.4 380 ± 13.3
Diabetic 198 ± 4.7 225 ± 11.5 248 ± 16.6∗
Kidney weight (mg/g BW)
Control 5.8 ± 0.4 5.6 ± 0.8 4.5 ± 0.7
Diabetic 5.9 ± 0.6 6.1 ± 1.0 6.7 ± 0.9∗
UAE (μg/day)
Control 110 ± 7.3 121 ± 8.1 137 ± 14.7
Diabetic 116 ± 5.7 125 ± 9.4 458 ± 24.5∗
HbA1c (%)
Control 3.7 ± 0.4 3.8 ± 0.6 3.8 ± 0.5
Diabetic 3.8 ± 0.3 4.3 ± 0.7 7.8 ± 0.9∗
Data are means ± SEM; ∗P<0.05 versus the control group. BW: body
weight; UAE: urinary albumin excretion; HbA1c: hemoglobin A1c.
several studies have shown that MT protein expression is
increased in the kidney of diabetic animals [16–18], the
cellulardistributionofMTshasnotbeenaddressed.Ourdata
providetheﬁrstevidencefortheexpressionproﬁleofMT-1/-
2 in the diabetic kidney. We speculate that MT-1/-2 is highly
induced in proximal tubular epithelial cells in compensation
for oxidative stress induced by high glucose.
Our study has potential limitations. First, we speculated
that MT-1/-2 expression was upregulated by ROS, but
further studies are needed to elucidate the underlying
mechanisms. Although Zn is known to induce the gene and
protein expression of MTs [24], this essential trace element
is unlikely to be involved in our ﬁndings because the same
chow was provided to the control and diabetic rats. In
this study, we showed that high-glucose-stimulated MT-1/-
2 expression was attenuated by vitamin E in vitro,b u tw e
have no data about diabetic rats treated by vitamin E. MT-
1/-2 expression in the diabetic state may diﬀer between cells
andtissues,andthemechanismsbywhichotherantioxidants
regulate the expression of MT remain unclear. Further
studies are needed to elucidate these issues. Second, it is still
controversial whether site-speciﬁc induction of MT plays an
important role in diabetic nephropathy. Podocyte-speciﬁc
overexpression of MT reduced diabetic nephropathy in
transgenic mice [25]. However, no studies have investigated
whether MT expression in proximal tubular epithelial cells
has a protective eﬀect in diabetic animal models. Therefore,
diabetes models using MT-knockout mice are needed to
answer this question.
In conclusion, renal ROS, which are induced by diabetes,
upregulateMT-1/-2expressioninproximaltubularepithelial
cellsofthekidney.OurresultssuggestthatMT-1/-2mightbe
a novel therapeutic target to treat diabetic nephropathy.
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